Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Woessner

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
Der Nervenarzt|October 3, 1998
[Value of antibody titers for diagnosis of neuroborreliosis]R Woessner, J Treib, A Haass, et al.
Neurology|November 18, 1998
Clinical and serologic follow-up in patients with neuroborreliosisJ Treib, A Fernandez, A Haass, et al.
Anticancer Research|August 23, 2000
Comparison of three approaches to doxorubicin therapy: free doxorubicin, liposomal doxorubicin, and beta-glucuronidase-activated prodrug (HMR 1826)R Woessner, Z An, X Li, et al.
European Neurology|February 25, 2000
Chronic fatigue syndrome in patients with Lyme borreliosisJ Treib, M T Grauer, A Haass, et al.
Zentralblatt Fur Bakteriologie : International Journal of Medical Microbiology|November 11, 1998
Prevalence of antibodies to tick-borne encephalitis virus and Borrelia burgdorferi sensu lato in samples from patients with abnormalities in the cerebrospinal fluidJ Treib, R Woessner, M T Grauer, et al.
Gesundheitswesen (Bundesverband Der Arzte Des Offentlichen Gesundheitsdienstes (Germany))|October 11, 2002
[Studies on the importance of tick-borne encephalitis in Rhineland-Pfalz]M Pietsch, M Vogt, J Süss, et al.
Infection|September 1, 1996
Tick-borne encephalitis diagnosis in patients with inflammatory changes in the cerebrospinal fluid in a region with very low prevalenceJ Treib, A Haass, S T Kiessig, et al.
Infection|December 21, 2006
Long-term antibiotic treatment with roxithromycin in patients with multiple sclerosisR Woessner, M T Grauer, A Frese, et al.
CPT: Pharmacometrics & Systems Pharmacology|February 24, 2016
Population PK-PD Model for Tolerance Evaluation to the p38 MAP Kinase Inhibitor BCT197S De Buck, W Hueber, A Vitaliti, et al.
Respiratory Medicine|September 21, 2010
Indacaterol once-daily is equally effective dosed in the evening or morning in COPDH Magnussen, C Verkindre, D Jack, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Der Nervenarzt|October 3, 1998
[Value of antibody titers for diagnosis of neuroborreliosis]R Woessner, J Treib, A Haass, et al.
Neurology|November 18, 1998
Clinical and serologic follow-up in patients with neuroborreliosisJ Treib, A Fernandez, A Haass, et al.
Anticancer Research|August 23, 2000
Comparison of three approaches to doxorubicin therapy: free doxorubicin, liposomal doxorubicin, and beta-glucuronidase-activated prodrug (HMR 1826)R Woessner, Z An, X Li, et al.
European Neurology|February 25, 2000
Chronic fatigue syndrome in patients with Lyme borreliosisJ Treib, M T Grauer, A Haass, et al.
Zentralblatt Fur Bakteriologie : International Journal of Medical Microbiology|November 11, 1998
Prevalence of antibodies to tick-borne encephalitis virus and Borrelia burgdorferi sensu lato in samples from patients with abnormalities in the cerebrospinal fluidJ Treib, R Woessner, M T Grauer, et al.
Gesundheitswesen (Bundesverband Der Arzte Des Offentlichen Gesundheitsdienstes (Germany))|October 11, 2002
[Studies on the importance of tick-borne encephalitis in Rhineland-Pfalz]M Pietsch, M Vogt, J Süss, et al.
Infection|September 1, 1996
Tick-borne encephalitis diagnosis in patients with inflammatory changes in the cerebrospinal fluid in a region with very low prevalenceJ Treib, A Haass, S T Kiessig, et al.
Infection|December 21, 2006
Long-term antibiotic treatment with roxithromycin in patients with multiple sclerosisR Woessner, M T Grauer, A Frese, et al.
CPT: Pharmacometrics & Systems Pharmacology|February 24, 2016
Population PK-PD Model for Tolerance Evaluation to the p38 MAP Kinase Inhibitor BCT197S De Buck, W Hueber, A Vitaliti, et al.
Respiratory Medicine|September 21, 2010
Indacaterol once-daily is equally effective dosed in the evening or morning in COPDH Magnussen, C Verkindre, D Jack, et al.
Pageof 3